12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Company News  |  Deals

Merus, OcellO deal

The companies partnered to screen human bispecific antibodies from Merus - called Biclonics - for cancer. OcellO will use its 3D cell culture-based screening technology...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >